| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.008 | 0.9 |
| mRNA | XMD11-85h | GDSC1000 | pan-cancer | AAC | -0.0076 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | necrostatin-7 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |